Forward Pharma A/S (FWP): Price and Financial Metrics

Forward Pharma A/S (FWP): $1.95

0.14 (+7.73%)

POWR Rating

Component Grades













Add FWP to Watchlist
Sign Up

Industry: Biotech



in industry

FWP Stock Price Chart Interactive Chart >

Price chart for FWP

FWP Price/Volume Stats

Current price $1.95 52-week high $6.48
Prev. close $1.81 52-week low $1.50
Day low $1.94 Volume 43,300
Day high $2.06 Avg. volume 7,484
50-day MA $2.83 Dividend yield N/A
200-day MA $4.17 Market Cap 13.83M

Forward Pharma A/S (FWP) Company Bio

Forward Pharma A/S is a Danish biopharmaceutical company developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. The company was founded in 2005 and is based in Copenhagen, Denmark.

FWP Latest News Stream

Event/Time News Detail
Loading, please wait...

FWP Latest Social Stream

Loading social stream, please wait...

View Full FWP Social Stream

Latest FWP News From Around the Web

Below are the latest news stories about FORWARD PHARMA A that investors may wish to consider to help them evaluate FWP as an investment opportunity.

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shar

Yahoo | December 19, 2022

Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review

COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Patent Office (the “EPO”) has denied Forward’s petition for review (the “Petition”) of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding (“Opposition Proceeding”).The EBA’s rejection o

Yahoo | December 6, 2022

Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021

COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was $1.9 million, or $0.02 per share, versus a net loss of $6.4 million, or $0.07 per share, for the year ended December 31, 2020. Our research, development, general and administrative costs in

Yahoo | April 8, 2022

Read More 'FWP' Stories Here

FWP Price Returns

1-mo N/A
3-mo -37.50%
6-mo -52.90%
1-year -64.55%
3-year -70.90%
5-year -91.90%
2022 0.00%
2021 -15.08%
2020 8.41%
2019 18.77%
2018 -78.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7356 seconds.